SparingVision SA, a developer of gene therapies for retinal diseases, has appointed Kalliopi Stasi as chief medical officer to advance the company’s therapies towards registration and commercialisation. Dr Stasi, an ophthalmologist, has over 30 years’ experience in research and biopharmaceuticals, holding leadership roles at Novartis, SalioGen and Adverum, especially in inherited retinal diseases and age-related macular degeneration (AMD). SparingVision’s lead programme, SPVN06, is currently enrolling a Phase 2 study in retinitis pigmentosa and is planning a Phase 2 trial in geographic atrophy secondary to dry AMD.
Copyright 2025 Evernow Publishing Ltd